Triple-Negative Breast Cancer Clinical Trials in Shanghai, Shanghai Municipality
16 recruitingShanghai, Shanghai Municipality, China
Showing 1–16 of 16 trials
Recruiting
Phase 2
Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.
TNBC - Triple-Negative Breast CancerBrain Metastasases
Fudan University58 enrolled1 locationNCT07638852
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 3
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.524 enrolled1 locationNCT06279364
Recruiting
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University300 enrolled1 locationNCT07551050
Recruiting
Phase 3
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Triple-Negative Breast Cancer
Fudan University134 enrolled1 locationNCT05806060
Recruiting
Phase 3
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Breast CancerTriple-Negative Breast Cancer
Fudan University764 enrolled15 locationsNCT05909332
Recruiting
Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled2 locationsNCT07111832
Recruiting
Phase 3
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University606 enrolled1 locationNCT05862064
Recruiting
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Triple-Negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.52 enrolled1 locationNCT06471205
Recruiting
Phase 2
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
TNBC - Triple-Negative Breast Cancer
Fudan University60 enrolled1 locationNCT06786026
Recruiting
Phase 2
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.160 enrolled1 locationNCT06492005
Recruiting
Phase 2
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University74 enrolled1 locationNCT06387628
Recruiting
Phase 4
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
Triple-Negative Breast CancerCarcinoma BreastInvasive Ductal Carcinoma, Breast
Fudan University1,072 enrolled34 locationsNCT04790305
Recruiting
Phase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
Fudan University424 enrolled2 locationsNCT05999149
Recruiting
Phase 3
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Triple-Negative Breast Cancer
Fudan University223 enrolled1 locationNCT05760378
Recruiting
Phase 3
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Triple-Negative Breast CancerMetastatic Breast CancerMutation
Fudan University203 enrolled1 locationNCT05954442